Eric G Stefanich

Dr. Eric G Stefanich


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in Biochemical Pharmacology
Verified
Journal Article
Closed access
ESEric G Stefanich
Eric G Stefanich
JRJulie Rae
Julie Rae
SSSiddharth Sukumaran
Siddharth Sukumaran
JLJeff Lutman
Jeff Lutman
ALAnnemarie Lekkerkerker
Annemarie Lekkerkerker
AHAnn Herman
Ann Herman

29 December 2010 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
YZY Zheng
Y Zheng
HSH Scheerens
H Scheerens
JDJ C Davis
J C Davis
RDR Deng
R Deng
SFS K Fischer
S K Fischer
ESEric G Stefanich
Eric G Stefanich

1 November 2008 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
ESEric G Stefanich
Eric G Stefanich
SRSong Ren
Song Ren
DDDimitry M. Danilenko
Dimitry M. Danilenko
ALAmy Lim
Amy Lim
ASAn Song
An Song
PFPaul J. Fielder
Paul J. Fielder
B cell-activating factor receptor 3 (BR3)-Fc is an IgG1-receptor dimeric fusion protein that has multiple O-linked glycosylation sites and sialylation levels that can vary in the manufacturing process. Increased sialic acid levels resulted from increased site occupancy with the O-linked N-acetylgalactosamine (GalNAc-Gal), but because the ratio of sialic acid per mole of oligosaccharide remained approximately 1, this led to increased asialo terminal GalNAc. Previous studies have demonstrated an effect of terminal asialo Gal or GalNAc on the clearance of glycoproteins due to uptake and degradation by lectin receptors in the liver. However, the previous studies examined N-linked oligosaccharides, and there are less data regarding O-linked oligosaccharides. The objective of these studies was to determine the effects on the pharmacokinetics and distribution of the asialo terminal GalNAc and varying amounts of sialic acid residues on BR3-Fc. The results of the data presented here suggest that exposed Gal on the desialylated BR3-Fc led to rapid clearance due to uptake and degradation in the liver that was associated with nonparenchymal cells. It is interesting to note that the data indicated a decreased clearance and increased exposure of BR3-Fc as the sialic acid levels increased, even though increased sialic acid was associated with increased asialo GalNAc. Therefore, the exposed GalNAc did not seem to play a role in the clearance of BR3-Fc; although the Gal linked to the hydroxyl group at position 3 may have prevented an interaction. Because we did not see uptake of desialylated BR3-Fc in hepatocytes where the asialoglycoprotein receptor is localized, this nonparenchymal cell lectin may have preference for O-linked glycoproteins.

30 April 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
RYRajbharan Yadav
Rajbharan Yadav
SSSiddharth Sukumaran
Siddharth Sukumaran
TZTanja S. Zabka
Tanja S. Zabka
JLJinze Li
Jinze Li
AOAmy Oldendorp
Amy Oldendorp
MOMeric A Ovacik
Meric A Ovacik
The T cell-dependent bispecific (TDB) antibody, anti-CD79b/CD3, targets CD79b and CD3 cell-surface receptors expressed on B cells and T cells, respectively. Since the anti-CD79b arm of this TDB binds only to human CD79b, a surrogate TDB that binds to cynomolgus monkey CD79b (cyCD79b) was used for preclinical characterization. To evaluate the impact of CD3 binding affinity on the TDB pharmacokinetics (PK), we utilized non-tumor-targeting bispecific anti-gD/CD3 antibodies composed of a low/high CD3 affinity arm along with a monospecific anti-gD arm as controls in monkeys and mice. An integrated PKPD model was developed to characterize PK and pharmacodynamics (PD). This study revealed the impact of CD3 binding affinity on anti-cyCD79b/CD3 PK. The surrogate anti-cyCD79b/CD3 TDB was highly effective in killing CD79b-expressing B cells and exhibited nonlinear PK in monkeys, consistent with target-mediated clearance. A dose-dependent decrease in B cell counts in peripheral blood was observed, as expected. Modeling indicated that anti-cyCD79b/CD3 TDB’s rapid and target-mediated clearance may be attributed to faster internalization of CD79b, in addition to enhanced CD3 binding. The model yielded unbiased and precise curve fits. These findings highlight the complex interaction between TDBs and their targets and may be applicable to the development of other biotherapeutics.

7 November 2000 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
ESEric G Stefanich
Eric G Stefanich
CCCatherine Carlson-Zermeno
Catherine Carlson-Zermeno
KMKaren McEvoy
Karen McEvoy
MRMike Reich
Mike Reich
PFPaul J. Fielder
Paul J. Fielder

8 July 2023 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
RYRajbharan Yadav
Rajbharan Yadav
SSSiddharth Sukumaran
Siddharth Sukumaran
JLJeff Lutman
Jeff Lutman
MMMayur S. Mitra
Mayur S. Mitra
WHWendy Halpern
Wendy Halpern
ESEric G Stefanich
Eric G Stefanich
MTBT1466A is a high-affinity TGFβ3-specific humanized IgG1 monoclonal antibody with reduced Fc effector function, currently under investigation in clinical trials as a potential anti-fibrotic therapy. Here, we characterized the pharmacokinetics (PK) and pharmacodynamics (PD) of MTBT1466A in mice and monkeys and predicted the PK/PD of MTBT1466A in humans to guide the selection of the first-in-human (FIH) starting dose. MTBT1466A demonstrated a typical IgG1-like biphasic PK profile in monkeys, and the predicted human clearance of 2.69 mL/day/kg and t1/2 of 20.4 days are consistent with those expected for a human IgG1 antibody. In a mouse model of bleomycin-induced lung fibrosis, changes in expression of TGFβ3-related genes, serpine1, fibronectin-1, and collagen 1A1 were used as PD biomarkers to determine the minimum pharmacologically active dose of 1 mg/kg. Unlike in the fibrosis mouse model, evidence of target engagement in healthy monkeys was only observed at higher doses. Using a PKPD-guided approach, the recommended FIH dose of 50 mg, IV, provided exposures that were shown to be safe and well tolerated in healthy volunteers. MTBT1466A PK in healthy volunteers was predicted reasonably well using a PK model with allometric scaling of PK parameters from monkey data. Taken together, this work provides insights into the PK/PD behavior of MTBT1466A in preclinical species, and supports the translatability of the preclinical data into the clinic.